Full-Time
Develops targeted radiation therapies for cancer
No salary listed
Senior
Fishers, IN, USA
Candidates should expect to be in the office at minimum 3 days per week; local candidates are preferred.
Get referrals →
You have ways to get a Telix Pharmaceuticals referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 19 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products aim to enhance treatment decisions and offer personalized therapies for conditions that lack effective solutions. The company focuses on areas such as prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its specialized products to healthcare providers and patients. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The company's goal is to improve the quality of life for patients while creating sustainable value for all stakeholders.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
Telix will partner with IRE ELiT S.A. (the radiopharmaceutical subsidiary of IRE Group), a leading provider of radioisotopes and radiopharmaceuticals for nuclear medicine, for the marketing and promotion of Illuccix(R) to healthcare professionals in France.
AUA25: Telix to showcase urologic pipeline at AUA: ProstACT Global, Illuccix(R) and zircaix(r).
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].